High performance liquid chromatography coupled with mass spectrometry for simultaneous determination of rivastigmine and its metabolite in rat plasma

Abstract Several studies on the pharmacokinetic parameters of antidementia drugs have reported that plasma concentration is linked to drugs’ efficacy and adverse effects. At present, there no quantitation method highly sensitive can be applied simultaneous monitoring pharmacokinetics rivastigmine its metabolites (NAP 226-90) in rat plasma. No methods fulfilling assay validation requirements US Food Drug Administration European Medicines Agency was also established. Therefore, this study developed a quantitative for measuring NAP 226-90 concentrations using high-performance liquid chromatography tandem mass spectrometry, examining samples after administration. Rat were prepared via protein precipitation method. The showed good fit over wide ranges 1–100 ng mL −1 0.5–50 , with lower limits quantification at 1 0.5 respectively. six healthy rats successfully determined, demonstrating feasibility applying Thus, research has sensitive, selective method, simultaneously quantify applicable study.